In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study
Iclaprim is a bacterial dihydrofolate reductase inhibitor in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections and hospital-acquired bacterial pneumonia caused by Gram-positive bacteria. Daptomycin, linezolid, and vancomycin are commonly used antibi...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
| Online Access: | http://dx.doi.org/10.1155/2017/3948626 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832547664624877568 |
|---|---|
| author | David B. Huang Stephen Hawser Curtis G. Gemmell Daniel F. Sahm |
| author_facet | David B. Huang Stephen Hawser Curtis G. Gemmell Daniel F. Sahm |
| author_sort | David B. Huang |
| collection | DOAJ |
| description | Iclaprim is a bacterial dihydrofolate reductase inhibitor in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections and hospital-acquired bacterial pneumonia caused by Gram-positive bacteria. Daptomycin, linezolid, and vancomycin are commonly used antibiotics for these indications. With increased selective pressure to these antibiotics, outbreaks of bacterial resistance to these antibiotics have been reported. This in vitro pilot study evaluated the activity of iclaprim against methicillin-resistant Staphylococcus aureus (MRSA) isolates, which were also not susceptible to daptomycin, linezolid, or vancomycin. Iclaprim had an MIC ≤ 1 µg/ml to the majority of MRSA isolates that were nonsusceptible to daptomycin (5 of 7 (71.4%)), linezolid (26 of 26 (100%)), or vancomycin (19 of 28 (66.7%)). In the analysis of time-kill curves, iclaprim demonstrated ≥ 3 log10 reduction in CFU/mL at 4–8 hours for tested strains and isolates nonsusceptible to daptomycin, linezolid, or vancomycin. Together, these data support the use of iclaprim in serious infections caused by MRSA nonsusceptible to daptomycin, linezolid, or vancomycin. |
| format | Article |
| id | doaj-art-b541499504814ccd8899e14228910a75 |
| institution | Kabale University |
| issn | 1712-9532 1918-1493 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases and Medical Microbiology |
| spelling | doaj-art-b541499504814ccd8899e14228910a752025-02-03T06:43:53ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1712-95321918-14932017-01-01201710.1155/2017/39486263948626In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot StudyDavid B. Huang0Stephen Hawser1Curtis G. Gemmell2Daniel F. Sahm3Motif BioSciences, New York, NY, USAIHMA Europe Sàrl, Route de I’Ile-au-Bois 1A, 1870 Monthey, Valais, SwitzerlandDepartment of Bacteriology, University of Glasgow Medical School, Glasgow, UKIHMA, Schaumburg, IL, USAIclaprim is a bacterial dihydrofolate reductase inhibitor in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections and hospital-acquired bacterial pneumonia caused by Gram-positive bacteria. Daptomycin, linezolid, and vancomycin are commonly used antibiotics for these indications. With increased selective pressure to these antibiotics, outbreaks of bacterial resistance to these antibiotics have been reported. This in vitro pilot study evaluated the activity of iclaprim against methicillin-resistant Staphylococcus aureus (MRSA) isolates, which were also not susceptible to daptomycin, linezolid, or vancomycin. Iclaprim had an MIC ≤ 1 µg/ml to the majority of MRSA isolates that were nonsusceptible to daptomycin (5 of 7 (71.4%)), linezolid (26 of 26 (100%)), or vancomycin (19 of 28 (66.7%)). In the analysis of time-kill curves, iclaprim demonstrated ≥ 3 log10 reduction in CFU/mL at 4–8 hours for tested strains and isolates nonsusceptible to daptomycin, linezolid, or vancomycin. Together, these data support the use of iclaprim in serious infections caused by MRSA nonsusceptible to daptomycin, linezolid, or vancomycin.http://dx.doi.org/10.1155/2017/3948626 |
| spellingShingle | David B. Huang Stephen Hawser Curtis G. Gemmell Daniel F. Sahm In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study Canadian Journal of Infectious Diseases and Medical Microbiology |
| title | In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study |
| title_full | In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study |
| title_fullStr | In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study |
| title_full_unstemmed | In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study |
| title_short | In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study |
| title_sort | in vitro activity of iclaprim against methicillin resistant staphylococcus aureus nonsusceptible to daptomycin linezolid or vancomycin a pilot study |
| url | http://dx.doi.org/10.1155/2017/3948626 |
| work_keys_str_mv | AT davidbhuang invitroactivityoficlaprimagainstmethicillinresistantstaphylococcusaureusnonsusceptibletodaptomycinlinezolidorvancomycinapilotstudy AT stephenhawser invitroactivityoficlaprimagainstmethicillinresistantstaphylococcusaureusnonsusceptibletodaptomycinlinezolidorvancomycinapilotstudy AT curtisggemmell invitroactivityoficlaprimagainstmethicillinresistantstaphylococcusaureusnonsusceptibletodaptomycinlinezolidorvancomycinapilotstudy AT danielfsahm invitroactivityoficlaprimagainstmethicillinresistantstaphylococcusaureusnonsusceptibletodaptomycinlinezolidorvancomycinapilotstudy |